$HRGN
Harvard Apparatus Regenerative Technology, Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008998 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.902M $522.0K
YoY Change 264.37% -58.96%
% of Gross Profit
Research & Development $303.0K $473.0K
YoY Change -35.94% -24.2%
% of Gross Profit
Depreciation & Amortization $14.00K $43.00K
YoY Change -67.44% -10.42%
% of Gross Profit
Operating Expenses $2.205M $995.0K
YoY Change 121.61% -47.52%
Operating Profit -$2.205M -$995.0K
YoY Change 121.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $28.00K $121.0K
YoY Change -76.86% -221.0%
Pretax Income -$2.177M -$874.0K
YoY Change 149.08% -56.21%
Income Tax
% Of Pretax Income
Net Earnings -$2.177M -$874.0K
YoY Change 149.08% -56.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20 -$0.09
Diluted Earnings Per Share -$0.20 -$0.09
COMMON SHARES
Basic Shares Outstanding 10.76M 9.388M
Diluted Shares Outstanding 10.76M 9.388M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $723.0K $466.0K
YoY Change 55.15% -42.18%
Cash & Equivalents $3.828M $516.0K
Short-Term Investments
Other Short-Term Assets $3.207M $438.0K
YoY Change 632.19% 10.61%
Inventory
Prepaid Expenses
Receivables $22.00K
Other Receivables $0.00
Total Short-Term Assets $3.930M $926.0K
YoY Change 324.41% -22.96%
LONG-TERM ASSETS
Property, Plant & Equipment $96.00K $330.0K
YoY Change -70.91% -35.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $238.0K $330.0K
YoY Change -27.88% -35.55%
TOTAL ASSETS
Total Short-Term Assets $3.930M $926.0K
Total Long-Term Assets $238.0K $330.0K
Total Assets $4.168M $1.256M
YoY Change 231.85% -26.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.273M $81.00K
YoY Change 1471.6% -64.32%
Accrued Expenses $4.153M $330.0K
YoY Change 1158.48% -49.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $346.0K
YoY Change
Total Short-Term Liabilities $9.109M $771.0K
YoY Change 1081.45% -23.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $58.00K
YoY Change -100.0%
Other Long-Term Liabilities $30.00K $46.00K
YoY Change -34.78% -24.59%
Total Long-Term Liabilities $30.00K $104.0K
YoY Change -71.15% 70.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.109M $771.0K
Total Long-Term Liabilities $30.00K $104.0K
Total Liabilities $9.139M $875.0K
YoY Change 944.46% -18.22%
SHAREHOLDERS EQUITY
Retained Earnings -$79.10M
YoY Change
Common Stock $108.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.971M $381.0K
YoY Change
Total Liabilities & Shareholders Equity $4.168M $1.256M
YoY Change 231.85% -26.72%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.177M -$874.0K
YoY Change 149.08% -56.21%
Depreciation, Depletion And Amortization $14.00K $43.00K
YoY Change -67.44% -10.42%
Cash From Operating Activities -$519.0K -$560.0K
YoY Change -7.32% -48.81%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.055M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -519.0K -560.0K
Cash From Investing Activities 0.000
Cash From Financing Activities 3.055M 0.000
Net Change In Cash 2.536M -560.0K
YoY Change -552.86% 423.36%
FREE CASH FLOW
Cash From Operating Activities -$519.0K -$560.0K
Capital Expenditures
Free Cash Flow -$519.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Liabilities
Liabilities
9139000
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11605507
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10761861
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9388407
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001563665
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10760871
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9388407
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2022Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-35853
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
BIOSTAGE, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5210462
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
84 October Hill Road, Suite 11
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Holliston
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01746
CY2022Q1 dei City Area Code
CityAreaCode
774
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
233-7300
CY2022Q1 dei Security12b Title
Security12bTitle
None
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 us-gaap Cash
Cash
723000
CY2021Q4 us-gaap Cash
Cash
1242000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
3105000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
102000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
295000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
3930000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1587000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
96000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
169000
CY2022Q1 us-gaap Assets
Assets
4168000
CY2021Q4 us-gaap Assets
Assets
1866000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1273000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
676000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1419000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
800000
CY2022Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
3250000
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
3250000
CY2022Q1 bstg Advancements On Private Placement
AdvancementsOnPrivatePlacement
3055000
CY2021Q4 bstg Advancements On Private Placement
AdvancementsOnPrivatePlacement
0
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9109000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4836000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59000
CY2021Q4 us-gaap Liabilities
Liabilities
4895000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10760871
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9388407
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
108000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
108000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
74036000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73801000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79115000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76938000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4971000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3029000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4168000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1866000
CY2022Q1 us-gaap Revenues
Revenues
0
CY2021Q1 us-gaap Revenues
Revenues
0
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
303000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
473000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1902000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
522000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2205000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
995000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2205000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-995000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
29000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
0
CY2022Q1 bstg Grant Income
GrantIncome
0
CY2021Q1 bstg Grant Income
GrantIncome
118000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
121000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2177000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-874000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10761861
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9388407
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2177000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
235000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4971000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1125000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-874000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
130000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
381000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2177000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-874000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
235000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
130000
CY2022Q1 us-gaap Depreciation
Depreciation
14000
CY2021Q1 us-gaap Depreciation
Depreciation
43000
CY2022Q1 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
-2000
CY2021Q1 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
-3000
CY2021Q1 bstg Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-55000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-193000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-136000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
597000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
50000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
621000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-97000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-519000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-560000
CY2022Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
3055000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3055000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2536000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-560000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1292000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1076000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3828000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
516000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79100000
CY2022Q1 us-gaap Cash
Cash
700000
CY2022Q1 bstg Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
3
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The process of preparing consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.</p>
CY2022Q1 us-gaap Cash
Cash
723000
CY2021Q4 us-gaap Cash
Cash
1242000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
3105000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3828000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1292000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
50000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
50000
CY2022Q1 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
50000
CY2017Q4 bstg Warrants To Be Remeasured Number
WarrantsToBeRemeasuredNumber
1044396
CY2017Q4 bstg Warrants To Be Modified Number
WarrantsToBeModifiedNumber
952184
CY2022Q1 bstg Warrants To Be Remeasured Number
WarrantsToBeRemeasuredNumber
92212
CY2022Q1 bstg Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExpired
92212
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.11
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1583786
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.16
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2501419
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.35
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
917633
CY2021 bstg Fair Value Assumptions Risk Free Interest Rates
FairValueAssumptionsRiskFreeInterestRates
0.0005
CY2021 bstg Fair Value Assumptions Expected Volatility Rates
FairValueAssumptionsExpectedVolatilityRates
174.54
CY2021 bstg Fair Value Assumptions Expected Terms
FairValueAssumptionsExpectedTerms
P0Y1M6D
CY2021 bstg Fair Value Assumptions Expected Dividend Rates
FairValueAssumptionsExpectedDividendRates
0
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2021Q4 bstg Fair Value Assumptions Warrant Liability Market Value
FairValueAssumptionsWarrantLiabilityMarketValue
2.30
CY2022Q1 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
628000
CY2022Q1 bstg Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
486000
CY2021Q4 bstg Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
577000
CY2022Q1 bstg Accrued Advisory Costs Current
AccruedAdvisoryCostsCurrent
188000
CY2021Q4 bstg Accrued Advisory Costs Current
AccruedAdvisoryCostsCurrent
151000
CY2022Q1 bstg Accrued Audit Services Current
AccruedAuditServicesCurrent
96000
CY2021Q4 bstg Accrued Audit Services Current
AccruedAuditServicesCurrent
59000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11000
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1419000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
800000
CY2021 bstg Increase Decrease In Accrual For Contingency Matter
IncreaseDecreaseInAccrualForContingencyMatter
3300000
CY2022Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
6000000.0
CY2022Q1 bstg Remaining Litigation Settlement Expenses Payable
RemainingLitigationSettlementExpensesPayable
5500000
CY2022Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
3300000
CY2022Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
2700000
CY2022Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
200000
CY2022Q1 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
6000000.0
CY2022Q1 us-gaap Loss Contingency Receivable Proceeds
LossContingencyReceivableProceeds
4000000.0
CY2022Q1 us-gaap Litigation Settlement Amount Awarded From Other Party
LitigationSettlementAmountAwardedFromOtherParty
4000000.0
CY2022Q1 us-gaap Loss Contingency Receivable
LossContingencyReceivable
1500000
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2022Q1 bstg Lessee Operating Lease Notice For Termination
LesseeOperatingLeaseNoticeForTermination
P180D
CY2022Q1 bstg Sublease Term
SubleaseTerm
P4M
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
29000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
142000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
169000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
142000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
169000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
30000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
30000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
30000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
30000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y4M13D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M19D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0918
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1024
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3986389
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3509335
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
91000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
54000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
152000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
142000

Files In Submission

Name View Source Status
0001558370-22-008998-index-headers.html Edgar Link pending
0001558370-22-008998-index.html Edgar Link pending
0001558370-22-008998.txt Edgar Link pending
0001558370-22-008998-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220331.xsd Edgar Link pending
tmb-20220331x10q.htm Edgar Link pending
tmb-20220331x10q_htm.xml Edgar Link completed
tmb-20220331xex31d1.htm Edgar Link pending
tmb-20220331xex31d2.htm Edgar Link pending
tmb-20220331xex32d1.htm Edgar Link pending
tmb-20220331xex32d2.htm Edgar Link pending
tmb-20220331_cal.xml Edgar Link unprocessable
tmb-20220331_def.xml Edgar Link unprocessable
tmb-20220331_lab.xml Edgar Link unprocessable
tmb-20220331_pre.xml Edgar Link unprocessable